Obmira 50mg Tablet ER
Marketer
Chemo Healthcare Pvt Ltd
Salt Composition
Mirabegron (50mg)
Overview Obmira 50mg Tablet ER
Obmira 50mg Extended-Release tablets alleviate overactive bladder symptoms such as urinary frequency, urgency, and incontinence. This medication relaxes bladder muscles, improving urine storage capacity. Always adhere to your doctor's prescribed dosage and duration. Obmira 50mg ER tablets may be taken with or without food; swallow whole, avoiding crushing or chewing. Discontinuing treatment prematurely may exacerbate symptoms; complete the prescribed course for optimal results. Potential side effects include constipation, headache, hypertension, rhinitis, urinary tract infections, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your physician immediately. Before starting treatment, disclose all other medications and pre-existing conditions, including pregnancy or breastfeeding. Individuals with hepatic or renal impairment require careful monitoring and regular check-ups as directed by their doctor.
Primary Ingredients of Obmira 50mg Tablet ER
No information provided. Please provide the text you wish me to rephrase.
Uses of Obmira 50mg Tablet ER
Managing symptoms associated with overactive bladder
Major Benefits of Obmira 50mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the 50mg Obmira Extended-Release tablet whole; avoid chewing, crushing, or fracturing it. Consumption may coincide with meals or be taken independently, though consistent timing is recommended.
Common Side effects of Obmira 50mg Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use Obmira 50mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for Obmira 50mg Extended-Release Tablets. Ingest the tablet whole; do not break, chew, or crush it. Consumption with or without food is acceptable, though consistent timing is recommended.
How Obmira 50mg Tablet ER works:
Obmira 50mg Extended-Release tablets contain a beta-3 adrenergic agonist. This medication's mechanism of action involves stimulating bladder beta-3 receptors, leading to detrusor muscle relaxation. The result is a reduction in urinary frequency, urgency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Obmira 50mg Extended-Release Tablets with alcohol. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
The extended-release Obmira 50mg tablet might pose risks during pregnancy. While human research is scant, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible hazards prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Obmira 50mg tablets are likely unsuitable for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Obmira 50mg Extended-Release Tablets.
KidneyCAUTION
For individuals with severely impaired kidney function, Obmira 50mg Extended-Release tablets require careful administration. Dosage modification of Obmira 50mg Extended-Release tablets may be necessary. Physician consultation is recommended.
LiverCAUTION
Patients with liver impairment should use Obmira 50mg Extended-Release tablets cautiously, potentially requiring dosage modification. Consultation with a physician is advised. Obmira 50mg Extended-Release tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Obmira 50mg Tablet ER :
Should you forget a dose of Obmira 50mg Extended-Release Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Obmira 50mg Tablet ER
| Label | Value |
|---|---|
| Chemical Type | Anilide-based compound |
| Developing Habits | No. |
| Type of Treatment | Urology |
| Behavioral Class | Beta-3 agonist for bladder control |





